Skip to content

Efficacy and Safety of SR46349B in Patients With Sleep Disorders in Fibromyalgia

Efficacy and Safety of SR46349B (1 and 5mg/Day) Administered During 8 Weeks in Patients With Sleep Disorders in Fibromyalgia: Multi-center, Randomized, Double-blind, Placebo-controlled Study.

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00313885
Enrollment
205
Registered
2006-04-12
Start date
2004-04-30
Completion date
2005-06-30
Last updated
2010-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgia, Sleep, Chronic Pain

Brief summary

Fibromyalgics frequently report sleep disturbances, in particular poor and unrefreshing sleep. Additionally, studies have reported that sleep problems, pain and mood disturbances are associated in patients with fibromyalgia. By improving the quality of sleep, complaints of poor and unrefreshing sleep, fatigue, pain, which are among the main components of this chronic pain disorder may be improved.

Detailed description

The purpose of this research study is to investigate the effectiveness and safety of 2 doses of the investigational product in subjects with sleep disorders with fibromyalgia as compared to placebo (a substance which contains no active ingredient). The study will last approximately 70 days and will include 7 office visits.

Interventions

oral administration

DRUGplacebo

oral administration

Sponsors

Sanofi
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
No

Inclusion criteria

* Each patient must fulfill the diagnosis criteria of fibromyalgia according to the American College of Rheumatology * Based on patient's information: * The patient must complain of unrefreshing sleep for at least 3 nights per week over the past month. * The patient spends at least 6.5 hours and not more than 9 hours, in bed, each night over the past 2 weeks. * Female patients of childbearing potential must have a confirmed negative pregnancy test at the end of the screening period and use an acceptable method of birth control throughout the study * Written, signed and dated informed consent must be obtained from each patient * Willing to abstain from taking any medication or treatment prohibited as per the protocol

Exclusion criteria

* Females who are lactating or pregnant * Night shift workers, and individuals who nap 3 or more times per week over the preceding month (nap: intentionally sleeping for more than 20 minutes during the day). * Consumption of beverage with caffeine (i.e. tea, coffee, or cola) comprising more than 2 cups or glasses per day * Past or Current medical history of any significant, severe, or unstable acute or chronically progressive medical or surgical disorder which may affect patient safety

Design outcomes

Primary

MeasureTime frame
refreshing quality of sleep measured by the patient sleep questionnaire8 weeks

Secondary

MeasureTime frame
sleep parameters (maintenance, duration, induction and quality)8 weeks

Countries

Canada, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026